Navigation Links
Imaging agents offer new view of inflammation, cancer
Date:10/7/2011

A series of novel imaging agents could make it possible to "see" tumors in their earliest stages, before they turn deadly.

The compounds, derived from inhibitors of the enzyme cyclooxygenase-2 (COX-2) and detectable by positron emission tomography (PET) imaging, may have broad applications for cancer detection, diagnosis and treatment.

Vanderbilt University investigators describe the new imaging agents in a paper featured on the cover of the October issue of Cancer Prevention Research.

"This is the first COX-2-targeted PET imaging agent validated for use in animal models of inflammation and cancer," said Lawrence Marnett, Ph.D., director of the Vanderbilt Institute of Chemical Biology and leader of the team that developed the compounds.

COX-2 is an attractive target for molecular imaging. It's not found in most normal tissues, and then it is "turned on" in inflammatory lesions and tumors, Marnett explained.

"As a tumor grows and becomes increasingly malignant, COX-2 levels go up," Marnett said.

To develop compounds that target COX-2 and can be detected by PET imaging, Jashim Uddin, Ph.D., research assistant professor of Biochemistry, started with the "core" chemical structures of the anti-inflammatory medicines indomethacin and celecoxib and modified them to add the element fluorine in various chemical configurations.

After demonstrating that the fluorinated compounds were selective inhibitors of COX-2, the investigators incorporated radioactive fluorine (18-F) into the most promising compound. Intravenous injection of this 18-F compound into animal models provided sufficient signal for PET imaging.

The researchers demonstrated the potential of this 18-F compound for in vivo PET imaging in two animal models: irritant-induced inflammation in the rat footpad and human tumors grafted into mice.

They showed that the 18-F compound accumulated in the inflamed foot, but not the non-inflamed foot, and that pre-treatment of the animals with celecoxib blocked the signal. In mice bearing both COX-2-positive and COX-2-negative human tumors, the 18-F compound accumulated only in the COX-2-positive tumor.

The studies support further development of these agents as probes for early detection of cancer and for evaluation of the COX-2 status of pre-malignant and malignant tumors.

"Because COX-2 levels increase during cancer progression in virtually all solid tumors, we think these imaging tools will have many, many different applications," Marnett said.


'/>"/>

Contact: Leigh MacMillan
leigh.macmillan@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. New research shows PET imaging effective in predicting lung cancer outcomes
2. Researchers transform iPhone into high-quality medical imaging device
3. Consider the breast and lungs when determining thoracic imaging protocols
4. Stanford brain imaging study shows physiological basis of dyslexia
5. New diagnostic imaging for lung cancer could prevent unnecessary surgery
6. Error rate higher in breast imaging reports generated by automatic speech recognition
7. Experts offer solutions at ACR Imaging Informatics Summit & Radiation Dose Monitoring Forum
8. New imaging technique visualizes cancer during surgery
9. Researchers utilize neuroimaging to show how brain uses objects to recognize scenes
10. New hybrid imaging device shows promise in spotting hard-to-detect ovarian cancer
11. New imaging test gives physicians better tool to diagnose Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... serving San Francisco and environs, is proud to announce an upgrade to the ... on the upgraded Yelp page on topics as diverse as Platelet Rich Plasma ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... entries to the 7th Edition of International Social Design Awards. , The ... Product Designers, System Designers, Governments and Institutions worldwide with realized projects and conceptual ...
(Date:2/26/2017)... York (PRWEB) , ... February 26, 2017 , ... ... products for wholesale distribution in North America, today announced it would be offering ... The company, which prides itself on crafting quality and unique baby clothing/feeding products, ...
(Date:2/26/2017)... ... ... ODH, Inc.™ announced today it will exhibit and speak at the 10th ... Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present on how ... management. , ODH will also have an exhibit booth where attendees may speak to ...
(Date:2/25/2017)... ... 25, 2017 , ... FCPX users now have the ability to sharpen a ... ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, ... spectrum tools users can visually see the color range effected with ease all within ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017 Medical information groups ... increase their self-service capabilities to manage inquiries from ... New research from consulting leader Best ... developed self-service website portals where HCPs can sign ... one of many findings to emerge from the ...
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... , Feb 24, 2017 ... Committee,s proposal for a new Board of Directors that ... The 2016-2017 Nomination Committee comprises representatives of the company,s ... quarter of 2016 who have accepted a seat on ... The composition of the 2016-2017 Nomination Committee was as ...
Breaking Medicine Technology: